[Executive Summary](index=1&type=section&id=Executive%20Summary) Puma Biotechnology reported significant financial improvements for Q2 2025, transitioning from a net loss to net income on both GAAP and non-GAAP bases, driven by increased NERLYNX® sales and improved operating cash flow and positive clinical development updates [Second Quarter 2025 Financial Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Puma Biotechnology reported significant financial improvements for Q2 2025, transitioning from a net loss to net income on both GAAP and non-GAAP bases, driven by increased NERLYNX® sales and improved operating cash flow Q2 2025 Financial Highlights | Metric | Q2 2025 | Q2 2024 | Change (YoY) | | :-------------------------------- | :------ | :------ | :----------- | | Product Revenue, Net | $49.2M | $44.4M | +$4.8M | | GAAP Net Income (Loss) | $5.9M | ($4.5M) | +$10.4M | | GAAP EPS (Basic & Diluted) | $0.12 | ($0.09) | +$0.21 | | Non-GAAP Adjusted Net Income (Loss) | $7.5M | ($2.5M) | +$10.0M | | Non-GAAP Adjusted EPS (Basic & Diluted) | $0.15 | ($0.05) | +$0.20 | | Net Cash Provided by Operating Activities | $14.1M | $1.0M | +$13.1M | - Product revenue, net, for the first six months of 2025 increased to **$92.3 million**, up from **$84.6 million** in the first six months of 2024[3](index=3&type=chunk) - Net income for the first six months of 2025 was **$8.8 million** (**$0.18 per share**), a significant improvement from a net loss of **$9.3 million** (**$0.19 per share**) in the prior year period[4](index=4&type=chunk) [CEO Commentary & Business Update](index=1&type=section&id=CEO%20Commentary%20%26%20Business%20Update) The CEO expressed satisfaction with revenue growth and positive net income, attributing growth to NERLYNX® demand and progress in alisertib's clinical development for breast and small cell lung cancer. Key clinical milestones are anticipated in Q4 2025 - Revenue growth in Q2 2025 and positive net income were driven by increased **NERLYNX® demand**[7](index=7&type=chunk) - Progress is being made in the clinical development of **alisertib** for chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer and small cell lung cancer[7](index=7&type=chunk) - Anticipated key milestones in the next 12 months include interim data presentations for **ALISCA™-Breast1** (Q4 2025) and **ALI-4201/ALISCA™-Lung1** (Q4 2025)[7](index=7&type=chunk) [Financial Performance Analysis](index=1&type=section&id=Financial%20Performance%20Analysis) Puma Biotechnology's Q2 2025 financial performance shows increased total revenue and a shift to net income, driven by NERLYNX® sales and reduced operating expenses, despite higher R&D investments [Revenue](index=1&type=section&id=Revenue) Total revenue for Q2 2025 increased by 11.3% year-over-year, primarily driven by higher net product revenue from NERLYNX® sales, complemented by a rise in royalty revenue Q2 Revenue (Millions) | Revenue Type | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (YoY) | | :---------------- | :----------------- | :----------------- | :----------- | | Product revenue, net | $49.2 | $44.4 | +$4.8 | | Royalty revenue | $3.2 | $2.7 | +$0.5 | | **Total revenue** | **$52.4** | **$47.1** | **+$5.3** | H1 Revenue (Millions) | Revenue Type | H1 2025 (Millions) | H1 2024 (Millions) | Change (YoY) | | :---------------- | :----------------- | :----------------- | :----------- | | Product revenue, net | $92.3 | $84.6 | +$7.7 | | Royalty revenue | $6.1 | $6.2 | -$0.1 | | **Total revenue** | **$98.4** | **$90.8** | **+$7.6** | [Operating Costs and Expenses](index=1&type=section&id=Operating%20Costs%20and%20Expenses) Total operating costs and expenses decreased in Q2 2025 and the first six months of 2025, primarily due to a significant reduction in selling, general and administrative expenses, despite increases in cost of sales and research and development Q2 Operating Costs and Expenses (Millions) | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Total operating costs and expenses | $45.8 | $49.3 | -$3.5 | | Cost of sales | $12.3 | $10.7 | +$1.6 | | Selling, general and administrative | $18.0 | $25.0 | -$7.0 | | Research and development | $15.5 | $13.6 | +$1.9 | H1 Operating Costs and Expenses (Millions) | Metric | H1 2025 (Millions) | H1 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Total operating costs and expenses | $87.8 | $95.3 | -$7.5 | | Cost of sales | $22.9 | $21.4 | +$1.5 | | Selling, general and administrative | $35.6 | $46.7 | -$11.1 | | Research and development | $29.3 | $27.2 | +$2.1 | [Cost of Sales](index=2&type=section&id=Cost%20of%20Sales) Cost of sales increased in Q2 and H1 2025, driven by higher royalty expenses and product costs from increased worldwide net sales - Cost of sales increased by **$1.6 million** in Q2 2025 and **$1.5 million** in the first six months of 2025, primarily due to higher royalty expense and product costs resulting from increased worldwide net sales[10](index=10&type=chunk) [Selling, General and Administrative Expenses](index=2&type=section&id=Selling%2C%20General%20and%20Administrative%20Expenses) SG&A expenses decreased significantly in Q2 and H1 2025, mainly due to lower legal fees related to prior year litigation - SG&A expenses decreased by **$7.0 million** in Q2 2025 and **$11.1 million** in the first six months of 2025, mainly due to lower legal fees associated with the AstraZeneca litigation in the prior year[11](index=11&type=chunk) [Research and Development Expenses](index=2&type=section&id=Research%20and%20Development%20Expenses) R&D expenses increased in Q2 and H1 2025, primarily driven by increased clinical study activity for alisertib - R&D expenses increased by **$1.9 million** in Q2 2025 and **$2.1 million** in the first six months of 2025, primarily driven by increased **alisertib study activity**[12](index=12&type=chunk) [Total Other Income (Expenses)](index=3&type=section&id=Total%20Other%20Income%20%28Expenses%29) The company reported total other income of $0.4 million in Q2 2025, a significant improvement from total other expenses of $2.0 million in Q2 2024, primarily due to a lower debt balance Q2 Total Other Income (Expenses) (Millions) | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Total other income (expenses) | $0.4 | ($2.0) | +$2.4 | H1 Total Other Income (Expenses) (Millions) | Metric | H1 2025 (Millions) | H1 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Total other income (expenses) | $1.2 | ($4.2) | +$5.4 | - The year-over-year decrease in other expenses for the first six months of 2025 was primarily due to a **lower debt balance** as the company continues to pay down its principal[13](index=13&type=chunk) [Net Income (Loss)](index=6&type=section&id=Net%20Income%20%28Loss%29) Puma Biotechnology achieved a net income of $5.9 million in Q2 2025, a substantial turnaround from a net loss of $4.5 million in Q2 2024, reflecting improved revenues and reduced operating expenses Q2 Net Income (Loss) (Millions) | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Net income (loss) | $5.9 | ($4.5) | +$10.4 | | Net income (loss) per share—basic | $0.12 | ($0.09) | +$0.21 | | Net income (loss) per share—diluted | $0.12 | ($0.09) | +$0.21 | H1 Net Income (Loss) (Millions) | Metric | H1 2025 (Millions) | H1 2024 (Millions) | Change (YoY) | | :-------------------------- | :----------------- | :----------------- | :----------- | | Net income (loss) | $8.8 | ($9.3) | +$18.1 | | Net income (loss) per share—basic | $0.18 | ($0.19) | +$0.37 | | Net income (loss) per share—diluted | $0.18 | ($0.19) | +$0.37 | [Financial Outlook](index=3&type=section&id=Financial%20Outlook) Puma Biotechnology provides Q3 and full-year 2025 guidance, projecting continued revenue growth and positive net income, with consistent full-year estimates [Third Quarter and Full Year 2025 Guidance](index=3&type=section&id=Third%20Quarter%20and%20Full%20Year%202025%20Guidance) Puma Biotechnology provided financial guidance for Q3 and the full year 2025, projecting continued revenue growth and positive net income, with consistent full-year estimates compared to previous outlooks Q3 and Full Year 2025 Guidance | Metric | Third Quarter 2025 | Full Year 2025 (current) | | :-------------------- | :----------------- | :----------------------- | | Net Product Revenue | $46-$48 million | $192–$198 million | | Royalty Revenue | $2-$3 million | $20–$24 million | | License Revenue | $0 million | $0 million | | Total Revenue | $48-$51 million | $212–$222 million | | Net Income/(Loss)* | $2-$4 million | $23–$28 million | | Gross to Net Adjustment | 22.5%–23.5% | 21.5%–22.0% | - The full year 2025 outlook for Net Product Revenue, Royalty Revenue, Total Revenue, and Net Income/(Loss) remains **consistent with previous estimates**[14](index=14&type=chunk) - The outlook does not include any adjustments for **tax valuation allowance**[16](index=16&type=chunk) [Company Information](index=3&type=section&id=Company%20Information) Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative cancer care products, with NERLYNX® as its primary commercial product and alisertib in Phase II clinical development [About Puma Biotechnology](index=3&type=section&id=About%20Puma%20Biotechnology) Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative cancer care products, with NERLYNX® as its primary commercial product and alisertib in Phase II clinical development for breast and lung cancers - Puma Biotechnology focuses on the development and commercialization of **innovative products** to enhance cancer care[18](index=18&type=chunk) - **NERLYNX® (neratinib, oral)** is approved for extended adjuvant treatment of early-stage HER2-positive breast cancer and in combination with capecitabine for advanced or metastatic HER2-positive breast cancer[18](index=18&type=chunk) - Puma is developing **alisertib**, an aurora kinase A inhibitor, with Phase II trials (ALISCA™-Lung1 and ALISCA™-Breast1) initiated for small cell lung cancer and HER2-negative, HR-positive metastatic breast cancer[19](index=19&type=chunk) [Product Information: NERLYNX](index=3&type=section&id=Product%20Information%3A%20NERLYNX) NERLYNX® (neratinib) is a kinase inhibitor indicated for specific HER2-positive breast cancer treatments, with important safety information regarding diarrhea, hepatotoxicity, and embryo-fetal toxicity, along with known drug interactions - NERLYNX® is indicated as a single agent for extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy[22](index=22&type=chunk) - It is also indicated in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens[22](index=22&type=chunk) - Key warnings and precautions include managing diarrhea, monitoring for hepatotoxicity, and advising on embryo-fetal toxicity[23](index=23&type=chunk) [Indications](index=3&type=section&id=Indications) NERLYNX® is indicated for extended adjuvant treatment of early-stage HER2-positive breast cancer and in combination with capecitabine for advanced or metastatic HER2-positive breast cancer - NERLYNX® is indicated as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy[22](index=22&type=chunk) - NERLYNX® is indicated in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting[22](index=22&type=chunk) [Important Safety Information](index=4&type=section&id=Important%20Safety%20Information) Important safety information for NERLYNX® includes managing diarrhea, monitoring for hepatotoxicity, and precautions regarding embryo-fetal toxicity and drug interactions - Diarrhea is a common adverse reaction and requires management through dose escalation or loperamide prophylaxis; severe or persistent diarrhea may require withholding or permanent discontinuation[23](index=23&type=chunk) - Hepatotoxicity monitoring is required monthly for the first 3 months, then every 3 months; Grade 3 abnormalities require withholding, and Grade 4 require permanent discontinuation[23](index=23&type=chunk) - NERLYNX® can cause fetal harm, and patients are advised to use effective contraception[23](index=23&type=chunk) - Common adverse reactions (≥ 5%) for single-agent NERLYNX include diarrhea, nausea, abdominal pain, fatigue, and vomiting[27](index=27&type=chunk) - Common adverse reactions (≥ 5%) for NERLYNX in combination with capecitabine include diarrhea, nausea, vomiting, decreased appetite, and constipation[27](index=27&type=chunk) - Drug interactions include avoiding concomitant use with proton pump inhibitors, strong CYP3A4 inhibitors, P-gp and moderate CYP3A4 dual inhibitors, and strong or moderate CYP3A4 inducers[27](index=27&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) Puma Biotechnology's financial statements reflect a positive shift from net loss to net income, supported by increased revenue and improved liquidity, with positive cash flow from operations [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) The consolidated statements of operations show a shift from net loss to net income for both the three and six months ended June 30, 2025, driven by increased total revenue and a reduction in total operating costs and expenses Consolidated Statements of Operations (Millions) - Three Months Ended June 30 | Metric (Millions) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :---------------------------- | :------------------------------- | :------------------------------- | | Total revenue | $52.4 | $47.1 | | Total operating costs and expenses | $45.8 | $49.3 | | Income (loss) from operations | $6.6 | ($2.2) | | Total other expenses, net | ($0.4) | ($2.0) | | Net income (loss) | $5.9 | ($4.5) | Consolidated Statements of Operations (Millions) - Six Months Ended June 30 | Metric (Millions) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :----------------------------- | :----------------------------- | | Total revenue | $98.4 | $90.8 | | Total operating costs and expenses | $87.8 | $95.3 | | Income (loss) from operations | $10.6 | ($4.5) | | Total other expenses, net | ($1.2) | ($4.2) | | Net income (loss) | $8.8 | ($9.3) | [Liquidity and Capital Resources](index=6&type=section&id=Liquidity%20and%20Capital%20Resources) Puma Biotechnology's liquidity position shows a decrease in cash and cash equivalents but an increase in marketable securities, resulting in a slight decrease in total cash, cash equivalents, and marketable securities compared to year-end 2024. Operating activities provided positive cash flow Liquidity and Capital Resources (Millions) | Metric (Millions) | June 30, 2025 | December 31, 2024 | | :---------------------------- | :------------ | :---------------- | | Cash and cash equivalents | $54.7 | $69.2 | | Marketable securities | $41.4 | $31.7 | | Total Cash, Cash Equivalents and Marketable Securities | $96.1 | $100.9 | | Working capital | $57.5 | $51.5 | | Current portion of long-term debt | $34.0 | $45.3 | | Long-term debt | $10.9 | $21.7 | | Stockholders' equity | $104.7 | $92.1 | Cash Flow Activity (Millions) | Cash Flow Activity (Millions) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :----------------------------- | :----------------------------- | | Operating activities | $17.7 | $12.3 |\ | Investing activities | ($9.7) | ($18.4) |\ | Financing activities | ($22.5) | ($11.3) |\ | Net decrease in cash, cash equivalents and restricted cash | ($14.5) | ($17.4) | [Non-GAAP Financial Measures](index=7&type=section&id=Non-GAAP%20Financial%20Measures) Puma Biotechnology presents non-GAAP adjusted net income (loss) by excluding stock-based compensation, offering a clearer view of core operational performance and facilitating period-over-period comparisons [Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss)](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Adjusted%20Net%20Income%20%28Loss%29) Puma Biotechnology provides non-GAAP adjusted net income (loss) by excluding stock-based compensation expense, which management believes offers a clearer view of operational performance and facilitates period-over-period comparisons Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) (Millions) - Three Months Ended June 30 | Metric (Millions) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :---------------------------- | :------------------------------- | :------------------------------- | | GAAP net income (loss) | $5.9 | ($4.5) | | Stock-based compensation - SG&A | $1.0 | $1.4 | | Stock-based compensation - R&D | $0.6 | $0.6 | | Non-GAAP adjusted net income (loss) | $7.5 | ($2.5) | | GAAP net income (loss) per share—basic | $0.12 | ($0.09) | | Non-GAAP adjusted basic net income (loss) per share | $0.15 | ($0.05) | Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) (Millions) - Six Months Ended June 30 | Metric (Millions) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :----------------------------- | :----------------------------- | | GAAP net income (loss) | $8.8 | ($9.3) | | Stock-based compensation - SG&A | $2.2 | $2.8 | | Stock-based compensation - R&D | $1.4 | $1.6 | | Non-GAAP adjusted net income (loss) | $12.4 | ($4.9) | | GAAP net income (loss) per share—basic | $0.18 | ($0.19) | | Non-GAAP adjusted basic net income (loss) per share | $0.25 | ($0.10) | - Non-GAAP measures exclude stock-based compensation expense, which represented approximately **4.9%** and **5.6%** of operating expenses (excluding cost of sales and acquired in-process R&D) for the three and six months ended June 30, 2025, respectively[32](index=32&type=chunk) [Additional Information](index=3&type=section&id=Additional%20Information) This section provides details on the Q2 2025 conference call, important forward-looking statements, and contact information for investor inquiries [Conference Call](index=3&type=section&id=Conference%20Call) Puma Biotechnology hosted a conference call on August 7, 2025, to discuss Q2 2025 financial results, business updates, and outlook, with access provided via dial-in and webcast - A conference call was held on **Thursday, August 7, 2025**, at **1:30 p.m. PT/4:30 p.m. ET** to report Q2 2025 financial results and provide a business update[17](index=17&type=chunk) - Access to the call was available via domestic and international dial-in numbers, and a live webcast with presentation slides was accessible on the company's investor relations website[17](index=17&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements regarding future milestones and financial results, which are subject to various risks and uncertainties that could cause actual results to differ materially from expectations - The press release includes forward-looking statements concerning anticipated milestones and estimates of future financial results for Q3 and full year 2025[26](index=26&type=chunk) - These statements involve risks and uncertainties, including regulatory approvals, clinical trial results, litigation, intellectual property changes, and global economic impacts, as detailed in SEC filings[26](index=26&type=chunk) - Readers are cautioned not to place undue reliance on these statements, and Puma assumes no obligation to update them except as required by law[26](index=26&type=chunk) [Contacts](index=5&type=section&id=Contacts) Contact information for Puma Biotechnology's management and investor relations, as well as for Russo Partners, is provided for inquiries - Contact information for Alan H. Auerbach and Mariann Ohanesian from Puma Biotechnology, Inc. is provided for inquiries[27](index=27&type=chunk) - Investor relations contacts from Russo Partners, David Schull and Olipriya Das, are also listed[27](index=27&type=chunk)

Financial Performance - Puma Biotechnology reported net NERLYNX revenue of $49.2 million in Q2'25, an increase of approximately 11% compared to $44.4 million in Q2'24[6, 7, 9] - The company also saw an increase of about 14% in net revenue from Q1'25 ($43.1 million) to Q2'25 ($49.2 million)[9, 10] - Inventory change improved from -$2.3 million in Q2'24 to -$1.3 million in Q2'25[8] - Inventory change improved from -$4.7 million in Q1'25 to -$1.3 million in Q2'25[11] Sales Volume - Puma Biotechnology sold 2,608 ex-factory bottles of NERLYNX in Q2'25[12] - This represents an approximate 4% increase compared to the 2,515 bottles sold in Q2'24[16] - There was also an approximate 12% increase in bottles sold from Q1'25 (2,338 bottles) to Q2'25 (2,608 bottles)[14, 16] - Inventory change in bottles improved from -132 in Q2'24 to -72 in Q2'25[13] - Inventory change in bottles improved from -250 in Q1'25 to -72 in Q2'25[15] Dosage Trends - Approximately 71% of patients in Q2'25 started NERLYNX at a reduced dose (fewer than 6 pills per day)[17] Global Expansion - NERLYNX has received regulatory approvals and been commercially launched in various regions through partnerships, including Australia/SE Asia, Israel, Canada, Latin America, Europe, Greater China, Middle East, North and West Africa, South Africa, Turkey, and South Korea[22]

Core Insights - Puma Biotechnology has an approved drug and decent sales but lacks market appreciation despite its ongoing pipeline [1] Company Overview - Puma Biotechnology is characterized as an "odd duck" in the biotech sector, having a unique position with an approved drug and reasonable sales figures [1] - The company has a continuing pipeline that suggests potential for future growth [1] Analyst Perspective - The author expresses cautious optimism regarding Puma Biotechnology, indicating that there are valid reasons for the current market sentiment [1] - The author has a background in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which informs their perspective on the company [1]

Group 1 - Momentum investing focuses on "buying high and selling higher" rather than traditional "buying low and selling high" strategies [1] - Fast-moving trending stocks can lose momentum if their future growth does not justify their high valuations, leading to potential downside risks for investors [2] - A safer investment strategy involves identifying bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score [3] Group 2 - Puma Biotech (PBYI) is highlighted as a strong candidate for momentum investing, with a recent price increase of 3.6% over the past four weeks [4] - PBYI has shown a significant price gain of 13.2% over the past 12 weeks, indicating its potential for sustained positive returns [5] - The stock has a beta of 1.29, suggesting it moves 29% more than the market, indicating fast-paced momentum [5] Group 3 - PBYI has a Momentum Score of B, suggesting it is an opportune time to invest in the stock to capitalize on its momentum [6] - The stock has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - PBYI is trading at a Price-to-Sales ratio of 0.71, indicating it is undervalued at 71 cents for each dollar of sales, providing room for growth [7] Group 4 - In addition to PBYI, there are other stocks that meet the criteria for fast-paced momentum at a bargain, which investors may consider [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, aiding in the identification of potential winning stocks [9]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investing can be risky as stocks may lose momentum when their valuations exceed future growth potential [1] - Identifying the right entry point for momentum stocks is challenging, and investors may end up with expensive shares that have limited upside [1] Group 2: Bargain Stocks with Momentum - Investing in bargain stocks that have recently shown price momentum may be a safer strategy [2] - The Zacks Momentum Style Score helps identify strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen identifies fast-moving stocks that are still attractively priced [2] Group 3: Puma Biotech (PBYI) Analysis - Puma Biotech (PBYI) has a four-week price change of 13.2%, indicating strong recent price momentum [3] - PBYI gained 1.5% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.29, suggesting it moves 29% higher than the market in either direction [4] Group 4: Valuation and Earnings Estimates - PBYI has a Momentum Score of A, indicating a favorable time to invest [5] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investor interest [6] - PBYI is trading at a Price-to-Sales ratio of 0.73, meaning investors pay 73 cents for each dollar of sales, indicating a reasonable valuation [6] Group 5: Additional Investment Opportunities - Besides PBYI, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to find potential winning stocks [8]

It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced. There are several stocks that currently pass through the screen and Puma Biotech (PBYI) ...

Core Viewpoint - Puma Biotechnology (PBYI) is currently identified as a strong value stock based on its favorable valuation metrics and earnings outlook [3][7]. Valuation Metrics - PBYI has a PEG ratio of 1.38, significantly lower than the industry average of 2.45, indicating potential undervaluation [4]. - The stock's P/B ratio stands at 1.61, compared to the industry's average of 3.01, suggesting a solid market value relative to its book value [5]. - PBYI's P/CF ratio is 3.53, which is attractive when compared to the industry's average of 12.71, highlighting its strong cash flow outlook [6]. Performance Insights - Over the past 52 weeks, PBYI's PEG ratio has fluctuated between 1.38 and 1.79, with a median of 1.51, indicating stable valuation [4]. - The P/B ratio has ranged from 1.47 to 4.86 in the last 12 months, with a median of 2.04, reflecting variability in market perception [5]. - The P/CF ratio has seen a range from 3.24 to 9.59, with a median of 4.20, further supporting the notion of undervaluation [6].

Financial Performance - Puma Biotechnology reported first-quarter 2025 adjusted earnings of 10 cents per share, exceeding the Zacks Consensus Estimate of 2 cents, compared to a loss of 5 cents per share in the same quarter last year [1] - Total revenues for the quarter were $46.0 million, surpassing the Zacks Consensus Estimate of $44.0 million, with a year-over-year increase of 5% attributed to higher product revenues [1][2] - Product revenues from Nerlynx totaled $43.1 million, reflecting a 7% year-over-year increase and slightly above the guidance of $41-$43 million, although there was a sequential decline of 20.7% [5] - Royalty revenues amounted to $2.9 million, down from $3.5 million in the year-ago quarter but exceeding the model estimate of $1.7 million [6] Cost Management - Total operating costs for the quarter were $42.0 million, a decrease of 9% year over year [6] - Selling, general and administrative expenses declined by 19.2% year over year to $17.6 million, primarily due to lower legal fees [6] - Research and development expenses totaled $13.8 million, reflecting a 1.5% year-over-year increase [7] Future Guidance - Puma Biotechnology maintained its financial guidance for 2025, expecting Nerlynx's product sales to be in the range of $192-$198 million and royalty revenues between $20-$24 million [10] - For the second quarter of 2025, Nerlynx product sales are anticipated to be between $48-$50 million, with royalty revenues expected to be in the range of $2-$3 million [11] Pipeline Developments - The company is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer, having in-licensed the rights from Takeda in 2022 [12] - Puma Biotechnology is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy in extensive-stage small-cell lung cancer, with interim data expected in the second half of 2025 [13] - A phase II study (ALISCA-Breast1) is also underway for alisertib in combination with endocrine treatment for chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data expected in the second half of 2025 [14] Stock Performance - Shares of Puma Biotechnology increased by 4.2% in after-hours trading on May 8 due to better-than-expected results [2] - The stock has risen 0.7% year to date, contrasting with an 8.4% decline in the industry [3]

Puma Biotechnology Earnings Call Commercial Update May 8, 2025 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statem ...

Core Insights - Puma Biotech reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing a significant improvement from a loss of $0.05 per share a year ago, resulting in an earnings surprise of 400% [1] - The company achieved revenues of $46 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.65% and increasing from $43.8 million year-over-year [2] Earnings Performance - Over the last four quarters, Puma Biotech has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company had an earnings surprise of 207.14% in the previous quarter, where it reported earnings of $0.43 per share against an expectation of $0.14 per share [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $49.38 million, and for the current fiscal year, it is $0.54 on revenues of $216.4 million [7] - The estimate revisions trend for Puma Biotech is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]